UBS Group’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
UBS Group's ACAD Position: Q3 2026 in Review
UBS Group increased its Acadia Pharmaceuticals (ACAD) stake by 60% in Q3 2026, buying an estimated $7.36M and bringing the position to 734,224 shares worth $14.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2991.
UBS Group first reported a position in ACAD in Q4 2014 and has held it in 48 quarters since. The position peaked at $22.8M in Q4 2024. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- UBS Group held 734,224 shares of Acadia Pharmaceuticals worth $14.8M as of Q3 2026.
- UBS Group bought 274,171 Acadia Pharmaceuticals shares in Q3 2026, an estimated $7.36M.
- Acadia Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #2991 holding.
- UBS Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 48 quarters since.
- UBS Group's Acadia Pharmaceuticals position peaked at $22.8M in Q4 2024.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.